Literature DB >> 2865103

Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys.

N I Chu, R L Chan, K M Hama, M D Chaplin.   

Abstract

Nafarelin acetate, [6-(3-(2-naphthyl)-D-Ala)]-luteinizing hormone-releasing hormone (LHRH), is a synthetic LHRH agonist. In the suppression of estrus in female rats, nafarelin acetate was about 200 times as potent as LHRH. We have studied the distribution and excretion of radiolabeled nafarelin acetate administered iv to rats and rhesus monkeys and have also compared the pharmacokinetics of nafarelin acetate to LHRH in these two species. Distribution of a single 100-micrograms dose [14C]nafarelin acetate into tissues in male rats was rapid and of the 13 tissues assayed, highest concentrations of radioactivity were observed in the kidneys, liver, and intestines. The urine to feces ratio of nafarelin-associated 14C was 4:1 in rhesus monkeys and 1:3 in rats. Nafarelin acetate and LHRH given iv to female rhesus monkeys in approximately equimolar doses (6.5 nmol/kg) had terminal plasma t1/2 values of 120 min and 33 min, and systemic clearance values of 2.7 ml/min/kg and 31.4 ml/min/kg, respectively. In female rats, the plasma t1/2 was 33.6 min for nafarelin acetate and 6.7 min for LHRH, and the systemic clearance values for nafarelin acetate and LHRH were 12.0 ml/min/kg and 57.6 ml/min/kg, respectively, after approximately equimolar doses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865103

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Disposition of detirelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and monkeys.

Authors:  R L Chan; W Ho; A S Webb; J A LaFargue; C A Nerenberg
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

2.  Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs.

Authors:  M Schwahn; N V Nagaraja; H Derendorf
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

3.  Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep.

Authors:  H Schreier; K J McNicol; D B Bennett; Z Teitelbaum; H Derendorf
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

Review 4.  Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

5.  Disposition of 3H-labelled buserelin continuously infused into rats.

Authors:  N Heinrich; E Albrecht; J Sandow; U Kertscher; D Lorenz; J Oehlke; H Berger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

Review 6.  Effects of gonadotrophin-releasing hormone outside the hypothalamic-pituitary-reproductive axis.

Authors:  D C Skinner; A J Albertson; A Navratil; A Smith; M Mignot; H Talbott; N Scanlan-Blake
Journal:  J Neuroendocrinol       Date:  2009-03       Impact factor: 3.627

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.